PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 4, 2004The FASEB Journal

A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does a recombinant antibody targeting phospholamban improve cardiac contractility in preclinical mouse and rat models?

Population

Neonatal rat and adult mouse ventricular cardiac myocytes, and diabetic mouse hearts

Design

Preclinical

Key result

In vivo expression of a recombinant antibody (PLN-Ab) targeting phospholamban accelerated calcium transient decay and enhanced cardiac contractility in diabetic mouse hearts.

Authors

MMMarkus MeyerDBDarrell D. BelkeSTSusanne U. Trost

Discussion

Loading...

Member takes

Overview

Supports PLN-Ab development for diabetic cardiomyopathy; leaves open translation to human heart failure.

Structured PICO

Does a recombinant antibody targeting phospholamban improve cardiac contractility in preclinical mouse and rat models?

P
Population
Neonatal rat and adult mouse ventricular cardiac myocytes, and diabetic mouse hearts
I
Intervention
Recombinant antibody-based protein (PLN-Ab) binding to the cytoplasmic domain of phospholamban, delivered via direct injection of adenovirus encoding PLN-Ab
O
Outcome
Cardiac contractility (measured by calcium transient decay, in vivo echocardiography, and ex vivo Langendorff perfused hearts)surrogate

In vivo expression of a recombinant antibody targeting phospholamban improves cardiac contractility in preclinical models, offering a potential novel therapeutic approach for heart failure.

Cite This Study

Meyer et al. (2004) studied Heart failure / Contractile dysfunction. Recombinant antibody-based protein (PLN-Ab) was evaluated on Cardiac contractility and calcium transient decay. In vivo expression of a recombinant antibody (PLN-Ab) targeting phospholamban accelerated calcium transient decay and enhanced cardiac contractility in diabetic mouse hearts.

synapsesocial.com/papers/6a15ce8f79ff98d0de4f2529https://doi.org/10.1096/fj.03-1231fje
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1AAV‐mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes2007 · 28 citations
  2. 2Adenovirus-Based Phospholamban Antisense Expression as a Novel Approach to Improve Cardiac Contractile Dysfunction2000 · 89 citations
  3. 3Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure2005 · 48 citations
  4. 4Targeting Phospholamban by Gene Transfer in Human Heart Failure2002 · 277 citations
  5. 5Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy2003 · 113 citations